New drug combo shows promise for tough lung cancer
NCT ID NCT05001971
First seen Jan 16, 2026 · Last updated May 10, 2026 · Updated 18 times
Summary
This study tested a combination of two drugs (anlotinib and penpulimab) in 65 people with small cell lung cancer whose disease had worsened after initial chemotherapy. The goal was to see if the combination could shrink tumors and help people live longer. The approach aims to control the cancer rather than cure it, as ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nong Yang
Changsha, Hunan, 410000, China
Conditions
Explore the condition pages connected to this study.